Complement and Neonatal Fc Receptor Inhibitors in Myasthenia Gravis (MG), Highlighting CHAMPION MG (ravulizumab) and ADAPT (efgartigimod) trials

Elie Naddaf, MD, interviews James Howard, MD, about the use of complement and the neonatal Fc receptor inhibitors in myasthenia gravis (MG), highlighting CHAMPION MG (ravulizumab) and ADAPT (efgartigimod) trials.